UNASSIGNED: 8184 Background: @entity10425 (C) or @entity1287 (HC) are commonly used to manage acute @entity158 crises in @entity1 with @entity3458 ( @entity3458 ). However, these medications often fail to provide adequate @entity158 relief, resulting in the need for alternative analgesics. Therefore, this study examined the characteristics associated with inadequate analgesic response to C and HC in @entity1 with @entity3458 . METHODS: Medical records were reviewed for 61 @entity1 with @entity3458 and a SS genotype who were prescribed either C- or HC-containing medications to manage an acute @entity158 crisis and had no evidence of severe @entity8 . Demographics, clinical characteristics and the number of ER visits/hospital admissions for an acute @entity158 crisis in which alternative analgesic therapy was administered, were recorded for the previous 12 months. RESULTS: There was substantial interpatient variability in the number of visits/admissions for an acute @entity158 crisis in the past year: mean (stdev) = 3.7    11. We found no significant differences in demographics or clinical characteristics between @entity1 who were above (n=11) and below (n=50) the mean number of visits/admissions, as shown in the table. However, there was a trend toward increased @entity1862 use among @entity1 above the mean number of visits/admissions (p=0.07). [Figure: see text] Conclusions: We found substantial interpatient variability in analgesic response to C and HC in @entity1 with @entity3458 , which could not be explained by demographic or clinical characteristics. These data suggest that other factors, such as @entity68819 or mu opioid receptor genotype, may contribute to the interpatient variability in C and HC response in @entity1 with @entity3458 . We are currently conducting a prospective study to determine the correlation between analgesic response, @entity68819 genotype, and @entity1286 concentrations following @entity10425 administration. No significant financial relationships to disclose.

Interpatient variability in analgesic response to @entity10425 and XXXX in @entity3458 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal or hepatic dysfunction'] @entity1862 :: ('MESH:D006918', 'Chemical') :: ['hydroxyurea'] @entity3458 :: ('MESH:D000755', 'Disease') :: ['SCD', 'sickle cell disease'] @entity1287 :: ('MESH:D006853', 'Chemical') :: ['hydrocodone'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity1286 :: ('MESH:D009020', 'Chemical') :: ['morphine'] @entity68819 :: ('107987479', 'Gene') :: ['cytochrome P450 2D6'] @entity10425 :: ('MESH:D003061', 'Chemical') :: ['codeine', 'Codeine']
@entity1287 :: (MESH:D006853,Chemical) :: ['hydrocodone']
